A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 136 participants.

Also called NCT02641652

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 136 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02641652
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02641652. Randomized; quadruple masking; primary purpose treatment. Start 2017-11 (anticipated); primary completion 2018-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension
Acronym
ATRAX
Condition
Hypertension
Intervention (Drug)
Sertraline
Intervention (Drug)
Placebo
Lead sponsor
University Hospital Olomouc (class: other)
Collaborator
Brno University Hospital (class: other)
Collaborator
St. Anne (class: not stated)
Collaborator
University Hospital Ostrava (class: other)
Collaborator
Tomas Bata Hospital, Czech Republic (class: other)
Collaborator
Prerov Hospital (class: not stated)
Collaborator
Valasske Mezirici Hospital (class: not stated)
Collaborator
Thomayer University Hospital (class: other)
Collaborator
Vsetin Hospital (class: not stated)

Record details

Record id
cardio:ct-nct02641652
Content hash
b16dad58b206d518a1be576457f4a77e119aeda03c4f778909d3b7b8c936245c